Join
Live feed
·
PRReleasevia Quantisnow
Gain Therapeutics Inc. logo

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

ByQuantisnow·Wall Street's wire, on your screen.
GANX· Gain Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GANX (Gain Therapeutics Inc.) and more on Quantisnow.